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Abstract
Background: Non-fasting triglyceride-rich lipoproteins cholesterol (TRL-C)
contributes to cardiovascular risk, in that it includes remnant cholesterol (RC).
TRL-C is computed as total C - [LDL-C + HDL-C]. Such calculation applies
only if LDL-C is directly measured, or obtained from a non-Friedewald's formula,
a method as yet never benchmarked against independent markers of TRL
burden.Methods: The Discriminant Ratio (DR) methodology was used in 120 type
2 diabetic patients in order: (i) to compute TRL-C from non-fasting lipids; (ii) to
establish the performance of TRL-C and TRL-C/apoA-I (vs. TG-based markers) to
grade TRLs and atherogenic dyslipidemia (AD); and (iii) to relate TRL-C with non-
fasting TG.Results: Depending on apoB<inf>100</inf> availability, TRL-C (mg/
dL) can be derived from non-fasting lipids in two ways: (a) total cholesterol (TC)
- [(0.0106 * TC - 0.0036 * TG + 0.017 * apoB<inf>100</inf> - 0.27) * 38.6] - HDL-
C; and (b) TC - [(0.0106 * TC - 0.0036 * TG + 0.017 * [0.6...
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Abstract
Background: Non-fasting triglyceride-rich lipoproteins cholesterol (TRL-C) contributes to cardiovascular risk, in that
it includes remnant cholesterol (RC). TRL-C is computed as total C - [LDL-C + HDL-C]. Such calculation applies only if
LDL-C is directly measured, or obtained from a non-Friedewald’s formula, a method as yet never benchmarked
against independent markers of TRL burden.
Methods: The Discriminant Ratio (DR) methodology was used in 120 type 2 diabetic patients in order: (i) to
compute TRL-C from non-fasting lipids; (ii) to establish the performance of TRL-C and TRL-C/apoA-I (vs. TG-based
markers) to grade TRLs and atherogenic dyslipidemia (AD); and (iii) to relate TRL-C with non-fasting TG.
Results: Depending on apoB100 availability, TRL-C (mg/dL) can be derived from non-fasting lipids in two ways:
(a) total cholesterol (TC) - [(0.0106 * TC - 0.0036 * TG + 0.017 * apoB100 - 0.27) * 38.6] - HDL-C; and (b) TC - [(0.0106 * TC -
0.0036 * TG + 0.017 * [0.65 * (TC - HDL-C) + 6.3] - 0.27) * 38.6] - HDL-C. Discrimination between log[TG] and TRL-C was
similar (DR 0.94 and 0.84, respectively), whereas that of log[TG]/HDL-C was better than TRL-C/apoA-I (DR 1.01 vs. 0.65;
p 0.0482). All Pearson’s correlations between pairs reached unity, allowing formulation of two unbiased equivalence
equations: (a) TRL-C = 97.8 * log[TG] - 181.9; and (b) TRL-C/apoA-I = 8.15 * (log[TG]/HDL-C) - 0.18.
Conclusions: TRL-C and log[TG] are as effective and interchangeable for assessing remnant atherogenic particles. For
grading TRL-AD, it is best to use log[TG]/HDL-C, inherently superior to TRL-C/apoA-I, while measuring the same
underlying variable.
Keywords: Remnant cholesterol, Triglycerides, Non-fasting, Chylomicrons, Lipoprotein, Diabetes, Atherogenic
dyslipidemia
Introduction
Cholesterol (C) in atherogenic particles other than low-
density lipoproteins (LDL) is an emerging risk factor
(RF) for ischemic heart disease, and is mostly found in
fasting and non-fasting triglyceride-rich lipoproteins
(TRLs). TRLs comprise two clusters: (i) chylomicrons
(CM; triglycerides (TG)-rich lipoproteins (TRLs) of in-
testinal origin) and their remnants (CMR), each carrying
one apolipoprotein (apo) B48); and (ii) very-low density
lipoproteins (VLDL; endogenous TRLs which originate
in the liver, and their relatively TG-depleted remnants
(VLDL-R), each carrying one apoB100) [1-13].
Table 1 describes the distribution of fasting and non-
fasting lipid particles, TRLs, and TRL remnants distribu-
tion, with respective contribution to total cholesterol,
TRL-cholesterol (TRL-C), and TRL-remnant cholesterol
(TRL-RC), alongside their major corresponding apolipo-
protein(s). Among TRLs, nonfasting residual TG-rich
particles are considered as a major contributor to re-
sidual vascular risk (RVR), even in patients on statins
whose LDL-C reaches target. These residual lipoproteins
are a blend of chylomicrons remnants (CM-R) and
very-low-density lipoprotein remnants (VLDL-R). Their
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atherogenicity is related to their ability to deliver choles-
terol in vessels walls.
Quantification of the cholesterol content of TG-rich
particles would be informative to better characterize
their nonfasting atherogenic load. However this would
require direct specific lipoproteins measurement beyond
routine clinical practice. For this reason, several authors
recently proposed to use a simple formula to measure
“remnant cholesterol” (RC) from standard nonfasting
lipids, “RC” being calculated as total C - (high-density-
lipoprotein (HDL)-C + LDL-C) [10,11]. Such equation
however measures TRL-C (the sum of CM-C, CMR-C,
VLDL-C and VLDL-R-C), and not RC. The latter is the
sum of CMR-C and VLDL-R-C, and accounts for only
two out of four components of TRL-C (Table 1).
As for RC, non-fasting TRL-C is usually not measured,
but derived according to the formula set out above: TRL-
C = total C minus [LDL-C +HDL-C] [8-11]. Whereas
LDL-C can be inferred from Friedewald’s equation in fast-
ing conditions, this calculation underestimates LDL-C in
moderate to severe hypertriglyceridemia (200-400 mg/dL),
and is inapplicable for fasting TG >400 mg/dL [14]. To
overcome this inaccuracy, a novel method for estimating
LDL-C from standard lipid profile using an adjustable fac-
tor for the TG:VLDL-C ratio was recently proposed by
Martin et al. [15,16].
By its very nature, Friedewald’s equation is unusable in
the non-fasting state. This is because in the presence of
elevated fasting TG or in non-fasting conditions, the
C-to-TG content of remnant lipoproteins (RLPs) in-
fringes the steady 1/5 ratio (20% C and 80% TG) at the
core of Friedewald’s method [14-20]. Determining non-
fasting TRL-C using a Friedewald-derived LDL-C level is
methodologically inadequate, as it merely equates TRL-C
with one-fifth of non-fasting TG, thus failing to provide
additional information beyond TG levels [8,10,11].
The lack of a simple and suitable method to determine
TRL-C currently limits its clinical use for evaluating
RVR, unless adequate alternatives to determine nonfast-
ing LDL-C are used. To circumvent this difficulty, an al-
ternative approach is to derive LDL-C from apoB100,
waiving the bias generated by applying a fixed C-to-TG
ratio that assumes constant and identical composition
for all RLPs. A disadvantage of this method is the re-
quirement for direct apoB100 measurement, limiting its
use unless apoB100 is inferred from routine lipids, as pre-
viously described [17-21].
The aims of this study were: (i) to provide relevant
equations to estimate TRL-C from non-fasting lipids, re-
gardless apoB100 availability; (ii) to establish the per-
formance and equivalence of TG-based markers vs.
TRL-C and TRL-C/apoA-I, a continuous estimator of
atherogenic dyslipidemia (AD); and (iii) to derive an un-
biased equation predicting TRL-C from non-fasting TG.
We used the Discriminant Ratio (DR) methodology
which standardizes comparisons between measurements
Table 1 Fasting and nonfasting lipid particles, triglyceride-rich lipoproteins (TRL), and TRL remnants distribution, with
respective contribution to total cholesterol, TRL-cholesterol and TRL-remnant cholesterol, alongside major corresponding
apolipoprotein(s)
Fasting Nonfasting
All lipoproteins Total cholesterol Apolipoprotein(s) All lipoproteins Total cholesterol Apolipoprotein(s)
(CM-R) (CM-R-C) (apoB48) CM CM-C apoB48
VLDL VLDL-C apoB100 CM-R CM-R-C apoB48
VLDL-R VLDL-R-C apoB100 VLDL VLDL-C apoB100
IDL IDL-C apoB100 VLDL-R VLDL-R-C apoB100
LDL LDL-C apoB100 IDL IDL-C apoB100
HDL HDL-C apoA-I; apoA-II LDL LDL-C apoB100
Lipoprotein(a) Lipoprotein(a)-C apoB100; apo(a) HDL HDL-C apoA-I; apoA-II
Lipoprotein(a) Lipoprotein(a)-C apoB100; apo(a)
TRLs TRL-cholesterol Apolipoprotein(s) TRLs TRL-cholesterol Apolipoprotein(s)
(CM-R) (CM-R-C) (apoB48) CM CM-C apoB48
VLDL VLDL-C apoB100 CM-R CM-R-C apoB48
VLDL-R VLDL-R-C apoB100 VLDL VLDL-C apoB100
VLDL-R VLDL-R-C apoB100
TRL remnants TRL-remnant cholesterol Apolipoproteins(s) TRL remnants TRL-remnant cholesterol Apolipoprotein(s)
(CM-R) (CM-R-C) (apoB48) CM-R CM-R-C apoB48
VLDL-R VLDL-R-C apoB100 VLDL-R VLDL-R-C apoB100
apo apolipoprotein, C cholesterol, CM chylomicron CM-R chylomicron remnant, HDL high-density lipoprotein, IDL intermediate-density lipoprotein, LDL low-density
lipoprotein, TRL triglyceride-rich lipoprotein, VLDL very-low density lipoprotein, VLDL-R very-low density lipoprotein remnant; parentheses refer to very low presence.
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by taking into account fundamental properties for asses-
sing imprecision and practical performance of tests de-
signed to quantify similar variables [19,22,23].
Methods
We studied 120 consecutive (86% white Caucasians) pa-
tients with T2DM, treated or not with lipid-lowering
drug(s) (LLD). Age; gender; diabetes duration; smoking
history; anthropometric indices; hypertension and meta-
bolic syndrome (MetS) prevalence, the latter defined ac-
cording to the harmonized criteria of Alberti et al. [24];
habitual ethanol intake; current glucose-lowering drugs,
and LLDs were analysed. Hypertension was defined as sys-
tolic ≥140 and/or diastolic blood pressure ≥90 mmHg,
and/or treatment with antihypertensive drugs. Glomerular
filtration rate was estimated (eGFR) using the Modifica-
tion of Diet in Renal Disease formula [25]. Albuminuria
was defined as an albumin excretion ≥30 μg.mg creatin-
ine-1.1.73 m2 from first-morning sample. Coronary and
peripheral artery disease (CAD and PAD) were diagnosed
as in [26], while stroke was defined according to UK Pro-
spective Diabetes Study (UKPDS) criteria [27]. Athero-
genic dyslipidemia (AD) was defined according to [28-30].
The following variables were measured in the non-
fasting state: glycated haemoglobin (HbA1c), total C;
HDL-C; TG; apoA-I and apoB100, with total C and TG
determined with SYNCHRON system (Beckman Coulter
Inc., Brea, CA); HDL-C with ULTRA-N-geneous reagent
(Genzyme Corporation, Cambridge, MA); apoA-I and
apoB100 by immunonephelometry (BNII Analyzer,
Siemens Healthcare Products GmbH, Marburg, Germany).
Nonfasting routine lipids, apoA-I and apoB100 were mea-
sured on two non-consecutive days for DR calculation,
with a 4-6 months’ interval between samples. A non-
HDL-C/apoB100 ratio >2.6 was an exclusion criterion be-
cause highly suggestive for Type III hyperlipoproteinemia
[31]. The within-subjects coefficients of variation were:
5.4% [total C]; 7.1% [HDL-C]; 4.9% (apoA-I) and 6.9%
[apoB100].
TRL-C was calculated from non-fasting lipids by sub-
tracting [LDL-C +HDL-C] from total C, with LDL-C
computed using Planella’s formula [17,19]:
LDL‐C mmol=Lð Þ ¼ 0:41 TC mmol=Lð Þ−0:32
TG mmol=Lð Þ þ 1:7
 apoB100 g=Lð Þ−0:27
Normal TRL-C values from 50 apparently-healthy lean
Caucasians, untreated with LLD and without familial
hypercholesterolemia or early-onset parental CV disease,
were (mg/dL): 24 (mean); 21 (median); 17 (SD); 2 (mini-
mum); 71 (maximum); 13 (percentile 25) and 29 (per-
centile 75).
Each patient gave written informed consent; the study
was performed in agreement with Helsinki’s Declaration;
Good Clinical Practice principles; and the local Institu-
tional Review Board.
Statistics
The Discriminant Ratio (DR) methodology compares
different tests measuring the same underlying physio-
logical variable by determining the ability of a test to dis-
criminate between different subjects, and the comparison
of discrimination between different tests as well as the
underlying correlation between pairs of tests adjusting for
attenuation due to within-subject variation [22]. In a com-
parison study where duplicates measurements are per-
formed in each subject, the measured between-subject
standard deviation (SDB) is calculated as the SD of the
subject mean values calculated from the 2 replicates.
 The standard mathematical adjustment to yield the
underlying between-subject SD (SDU) is: SDU =
√ (SD2B - SD
2
W/2);
 The within-subject variance (Vw) calculated (for m
repeat tests) as (Vw) = Σ(xj -xi )
2/(m-1)), the
within-subject SD (SDw) being its square root;
 The DR represents the ratio SDU/SDW
Confidence limits for DR’s and the testing for equiva-
lence of different DR’s were calculated and differences
were considered significant for p < 0.05. Given sample
size and number of replicates, the minimal detectable
significant difference in DR for the present study was
0.42. Coefficients of correlation between pairs of tests
(measured vs. estimated) were adjusted to include an es-
timate of the underlying correlation, as standard coeffi-
cients tend to underestimate the true correlation
between tests, due to within-subject variation [22].
Results are presented as means (±1 standard deviation
[SD]), or as proportions (%). The significance of differ-
ences between means was assessed by Student’s t test, or
by Welch’s test for data sets with significant differences
in SDs, and by Chi2 test for differences in proportions.
Results were considered statistically significant or non-
significant (NS) for p <0.05 or p ≥0.05, respectively.
Results
Patients’ characteristics are described in Table 2. Mean
age (1 SD) was 67 (11) years, with a male gender pre-
dominance. Mean body mass index was in the over-
weight range. Patients had long-standing diabetes (mean
duration 16 (9) years), with a majority also having hyper-
tension (89%), and a MetS phenotype (92%). Current
smokers amounted to 13%; habitual ethanol intake was
10 (18) U/week. Mean glycaemic control, as reflected by
HbA1c, was suboptimal at 7.79 (1.32)% (62 (10) mmol/
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mol). Overall microangiopathy prevalence was 58%: ret-
inopathy 37%; polyneuropathy 28% and/or (micro) albu-
minuria 29%.
Most patients were on LLDs: statins (81%) and/or
fibrates (38%). Current mean lipids and lipoproteins
values were illustrative of patients with the usual form of
T2DM, i.e. associated with central adiposity, insulin re-
sistance (IR) and MetS: low HDL-C with raised non-
HDL-C, apoB100, TG and TRL-C, together with a high
prevalence of AD (58%). Overall macroangiopathy preva-
lence was 33%: CAD [23%]; PAD [11%] and/or cerebro-
vascular disease [7%].
Figure 1 shows the plots of untransformed values on
two different days for TG; TRL-C; log[TG]/HDL-C; and
TRL-C/apoA-I, respectively. Relative median day-to-day
variations were: 36% (TG); 39% (TRL-C); 16% (log[TG]/
HDL-C); and 46% (TRL-C/apoA-I), respectively. Figure 1
also shows the heteroscedastic arrangement of the data
spread on repeat measurements.
The precision, discrimination and interrelation of each
non-fasting estimate, expressed as underlying between-
subject standard deviation (SDu), global within-subject
standard deviation (SDw), discriminant ratio (DR); and
measured Pearson’s product-moment correlation coeffi-
cients are shown in Table 3. For the log[TG] vs. TRL-C
comparison, the respective SDu/SDw (DRs) were 0.94
and 0.84, and the difference in discriminatory power be-
tween the two determinations did not reach statistical
significance. As regards the log[TG]/HDL-C vs. TRL-C/
apoA-I comparison, the respective DRs were 1.01 and
0.65, the discriminatory power of log[TG]/HDL-C being
significantly better than of TRL-C/apoA-I (p 0.0482).
The Pearson’s correlations between each pair of tests
were high, respectively 0.92 (log[TG] vs. TRL-C) and
0.89 (log[TG]/HDL-C vs. TRL-C/apoA-I), each correl-
ation reaching unity, once values were adjusted for at-
tenuation prior to correlation (Table 3).
Figure 2 shows the plots of untransformed values
(means of Day 1 and Day 2) for log[TG] vs. TRL-C, and
log[TG]/HDL-C vs. TRL-C/apoA-I. The equations of the
unbiased lines of equivalence relating each pair of tests
were:
TRL‐C mg=dLð Þ ¼ 98log non‐fasting TG½  mg=dLð Þ−182
TRL‐C=apoA‐I ¼ 8:15 log non‐fasting TG½ =HDL‐Cð Þ−0:18
Practically, these equations allow for calculating TRL-C
without bias from standard non-fasting lipids, depending
on apoB100 availability (units mg/dL):
1. apoB100 is available alongside standard non-fasting
lipids:
TRL‐C ¼ TC−½ð0:0106  TC−0:0036  TGþ 0:017
 apoB100−0:27Þ  38:6−HDL‐C
2. apoB100 level is not available, and is computed
according to [19]:
TRL‐C ¼ TC−½ð0:0106  TC−0:0036  TGþ 0:017
 0:65  TC‐HDL‐Cð Þ þ 6:3½ −0:27Þ
 38:6−HDL‐C
Discussion
Measuring TG represents an easy means to estimate the
combined mass of fasting or non-fasting TRLs, as surrogate
Table 2 Patients’ characteristics
n 120
Age Years 67 (11)
Diabetes duration Years 16 (9)
Male: female % 63: 37
Smoking§ 42-45-13
Body mass index kg.m-2 30.2 (5.6)
Waist circumference cm 106 (15)
Metabolic syndrome % 92
Hypertension % 89
Anti-dyslipidemic drug(s) % 92
Statin-fibrate-ezetimibe % 81-38-12
HbA1c % 7.79 (1.32)
HbA1c mmol.mol
-1 62 (10)
Glomerular filtration rate mL.min-1 1.73 m2 73 (27)
Albuminuria μg.mg creatinine-1 90 (240)
Atherogenic dyslipidemia % 58
Total cholesterol mg.dL-1 172 (34)
Non-HDL-C mg.dL-1 127 (33)
LDL-C mg.dL-1 91 (26)
TRL-C mg.dL-1 36 (20)
TG mg.dL-1 197 (101)
log[TG] mg.dL-1 2.23 (0.20)
apoB100 mg.dL
-1 89 (21)
apoA-I mg.dL-1 145 (25)
HDL-C mg.dL-1 44 (12)
log[TG]/HDL-C 0.057 (0.024)
TRL-C/apoA-I 0.28 (0.20)
Macroangiopathy % 33
Coronary artery disease % 23
Peripheral artery disease % 11
Transient ischemic attack/stroke % 7
Results are expressed as means (1 SD) or proportions, with nonfasting lipids
and lipoproteins values representing the means of Day 1 and Day 2. Apo
apolipoprotein, C cholesterol, HbA1c glycated haemoglobin, HDL high-density
lipoprotein, LDL low-density lipoprotein, TG trigylycerides, TRL TG-rich
lipoprotein; §never-former-current.
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for their cholesterol load. An excess of TRLs, including
RLPs, throughout the nycthemeron epitomizes CMR
conditions such the MetS, IR and the common form of
T2DM. Elevated levels of TRL-C contribute, alongside
LDL-C, to plaque formation and progression. TRL-C is
a modifiable driver of RVR. Whereas TG as such are
not atherogenic, the well-demonstrated association be-
tween fasting or non-fasting TG and CVD is underlied
by the atherogenicity of TRLs, especially that of RLPs
[2-6,8-11,32,33].
In fasting conditions, hypertriglyceridemia >150 mg/dL is
categorized as “elevated” VLDL, corresponding to TRL-C
levels >30 mg/dL. Such assumption of equivalence is
valid only if the composition of VLDL, in terms of C
and TG, is in a ratio of 1/5. This is not necessarily the
case in CMR states where non-VLDLTRLs (among which
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Figure 1 Plots of untransformed values obtained on day 1 (X axis) and day 2 (Y axis) for nonfasting triglycerides (TG) (upper left);
TG-rich lipoprotein cholesterol (TRL-C) (upper right); nonfasting log [TG]/high-density lipoprotein cholesterol (HDL-C) (lower left);
and TRL-C/apolipoprotein (apo) A-I (lower right) in 120 patients with type 2 diabetes.
Table 3 Precision and discrimination of nonfasting TG, TRL-C, and atherogenic dyslipidemia ratios expressed as between-
subject Standard Deviations (SDu), global within subject Standard Deviation (SDw), Discriminant Ratio (DR), and measured
Pearson’s correlation coefficients between pairs of variables [adjusted for attenuation]
SDu SDw DR CIs p Pearson’s coefficient
log[TG] 0.161 0.171 0.94 [0.72-1.19] 0.5604 0.92 [1.00]
TRL-C 15.20 18.06 0.84 [0.61-1.09]
log[TG]/HDL-C 0.0198 0.0195 1.01 [0.79-1.27] 0.0482 0.89 [1.00]
TRL-C/apoA-I 0.138 0.210 0.65 [0.40-0.90]
Values from nonfasting results of individual tests and means of their duplicates in 120 type 2 diabetes patients, with [2.5 - 97.5%] confidence intervals (CIs) for
DR’s. Apo apolipoprotein, C cholesterol, HDL high-density lipoprotein, TG triglycerides, TRL TG-rich lipoprotein. P values represented the significancies of the
differences between DRs of each pair of variables. For correlation between estimates, values were obtained from the mean of different measurements performed
on separate days.
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numerous RLPs) co-exist alongside VLDL. Likewise, in
non-fasting conditions, TRLs are further heterogeneous,
in size and composition, being populated by various
TG-enriched and relatively TG-depleted lipoproteins (in-
cluding remnants from the endogenous and exogenous
pathways). The C/TG ratio of non-fasting TRLs sub-
stantially differs from that of fasting TRLs, the latter
essentially consisting of standard VLDL with 20% chol-
esterol [1,3,13-17,20,21].
For this reason, recent articles on the usefulness of “RC”
as residual risk marker relied by default on Friedewald’s
formula to estimate the LDL-C component of the equa-
tion. Doing so, their authors did not distinguish TRL-C
from RC. Such an oversimplification ascribes to RC all the
observed risk of non-fasting TRL-C. Besides, their ration-
ale for extending the use of Friedewald’s equation to deter-
mine LDL-C in non-fasting samples, in place of a direct
assay, relied upon a linear relationship between calculated
and measured LDL-C in a reference subgroup, such a rela-
tionship being a self-fulfilling prophecy [8,10,11,14].
The present results provide unbiased and physiologically-
consistent equations to determine TRL-C from non-
fasting lipids, regardless apoB100 availability. As expected,
non-fasting TRL-C and log[TG] were highly correlated,
with adjusted Pearson’s coefficient reaching unity. Since
both measures have uniform precision and discrimination,
they provide similar information for ranking patients ac-
cording to non-fasting TRLs, and are interchangeable.
Yet, conceptually and educationally, determining TRL-C
as surrogate for TRLs is more attractive, since it quantifies
the atherogenic component directly involved in driving
CV risk, including all the cholesterol load from RLPs.
In this context, the DR method provides an unbiased
equivalence equation allowing to predict TRL-C from log
[TG], or vice-versa.
While the concept of low HDL-C as unconditional RF is
strongly debated, the coexistence of elevated fasting TG
together with low fasting HDL-C allows identifying pa-
tients with AD, in whom residual risk is particularly high,
even when on-statin LDL-C is controlled [28-30,33,34].
An explanation for the accrued RVR from AD in the fast-
ing state is that it could be a marker for high numbers of
postprandial TRLs and elevated non-fasting TRL-C. This
is supported by results from an ACCORD-Lipid sub-
study, in which fenofibrate similarly lowered non-fasting
TG in all T2DM participants, while reducing postprandial
apoB48 excursions only in individuals with elevated fasting
TG at baseline, a subgroup in which fenofibrate reduced
CV outcomes [35].
In the presence of fasting hypertriglyceridemia (>150
mg/dL), the HDL-C cutoffs defining AD (≤40 mg/dL
[men] and ≤50 mg/dL [women]) are transposable to non-
fasting conditions, because remnant TRLs have little influ-
ence on HDL-C. Contrariwise, there are currently no
standards or agreement defining (i) the upper physio-
logical value for non-fasting TG; (ii) the sampling time
after meal; and (iii) the lipid content and composition of
the previous meal. For all these reasons we suggest to use
either [TRL-C/apoA-I] or [log[TG]/HDL-C] to assess
postprandial AD as a continuous variable.
As the underlying correlation between TRL-C and log
[TG] on one hand, and between TRL-C/apoA-I and log
[TG]/HDL-C on the other hand, reached unity once
pre-analytical and analytical attenuation were taken into
account, these two approaches may be used interchange-
ably to assess equivalent biological measures. While
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Figure 2 Equivalence between tests. Left panel: plots of untransformed values of log[triglycerides (TG)] (X axis) vs. TG-rich lipoprotein cholesterol
(TRL-C) (Y axis). Right panel: plots of log[TG]/high-density lipoprotein cholesterol (HDL-C) (X axis) vs. TRL-C/apolipoprotein (apo) A-I (Y axis). The
equations of the two unbiased lines of equivalence relating each pair of measurements are provided on the graphs. All values obtained from the
means of nonfasting values measured on two different days in 120 patients with type 2 diabetes mellitus.
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there was no significant difference between the discrim-
inating performance of log[TG] compared to TRL-C, the
discrimination of the ratio log[(TG]/HDL-C was clearly
and significantly higher than the TRL-C/apoA-I ratio to
quantify the severity of non-fasting AD in patients at
high CMR. Given the perfect concordance between pairs
of measurements, the clinician may prefer to expressing
CV risk linked to TRL-C (intuitively more educational
than log[TG]), and to determine CV risk related to AD
by calculating log[TG]/HDL-C, which is superior to
TRL-C/apoA-I. The latter has the inconvenience to re-
quire apoA-I determination on top of routine lipids.
Regarding biometric equivalence between atherogenic-
antiatherogenic ratios, we previously reported that non-
HDL-C/HDL-C provides CV risk stratification similar to
the apoB100/apoA-I ratio [36].
In this study, the performance of the above measures
to that of a direct measurement of RC was not assessed,
since the latter is not part of routine risk assessment. As
regards cohort’s size, we compared the performance of
two means to assess the burden of atherogenic TRL in
120 patients, an ample number given the DR method-
ology, which only requires ≥20 samples with 2 replicates
as long as they represent a clinically-meaningful range
for the variable under study [see Appendix of [22] for a
detailed discussion on sample size requirements for esti-
mating DRs]. The fact that patients had T2DM in this
study does not limit the applicability of the findings,
since the metabolic and pathophysiological fundamentals
of TRL, CMR and RC are similar in diabetic and nondia-
betic subjects, at increasing levels along a continuum,
from normal to impaired fasting glucose, and from pre-
diabetes to T2DM [37,38].
In conclusion, estimating TRL-C requires formulas
which reflect the complex compositional changes in non-
fasting TRLs, the latter consisting of particles not ex-
clusively generated along the VLDL pathway, in which
TG-content is heterogeneous and changes dynamically.
We provide two unbiased equations to estimate the bur-
den of TRL-C based on routine nonfasting lipids, depend-
ing on apoB100 measurement availability. Our results
show that TRL-C and log[TG] are as effective and inter-
changeable to assess the atherogenic load of nonfasting
TRLs. However, to grade TRL-related AD, it is better to use
log[TG]/HDL-C, which is inherently superior to TRL-C/
apoA-I, while measuring the same underlying variable.
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